Peripheral blood involvement in angioimmunoblastic T-cell lymphoma: a case report and review of the literature.

Autor:	Jain G; Laboratory Oncology Unit, Dr. B.R.A.I.R.C.H, All India Institute of Medical Sciences New Delhi, India., Kumar C; Laboratory Oncology Unit, Dr. B.R.A.I.R.C.H, All India Institute of Medical Sciences New Delhi, India., Malhotra A; Laboratory Oncology Unit, Dr. B.R.A.I.R.C.H, All India Institute of Medical Sciences New Delhi, India., Mallick SR; Department of Pathology, All India Institute of Medical Sciences New Delhi, India., Bakhshi S; Department of Medical Oncology, Dr. B.R.A.I.R.C.H, All India Institute of Medical Sciences New Delhi, India., Chopra A; Laboratory Oncology Unit, Dr. B.R.A.I.R.C.H, All India Institute of Medical Sciences New Delhi, India.
Jazyk:	angličtina
Zdroj:	American journal of blood research [Am J Blood Res] 2020 Oct 15; Vol. 10 (5), pp. 257-265. Date of Electronic Publication: 2020 Oct 15 (Print Publication: 2020).
Abstrakt:	Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive variant of peripheral T-cell lymphoma, occurring in elderly patients without any gender predisposition. It accounts for 1-2% of all non-Hodgkin lymphoma. Although characterized by some peculiar histological features, diagnosis of AITL can sometimes be challenging and a definite diagnosis requires a complete immunophenotypic and molecular workup. Peripheral Blood (PB) involvement in AITL has not been studied in detail and there is a paucity of published data about leukemic presentation of AITL. We present a case of a 38-year-old female diagnosed as AITL with PB involvement. Flow cytometric (FCM) examination of PB showed 40% abnormal lymphoid cells which were CD45+, CD4+, CD2+, cCD3+, CD5+, CD10+, CD16+ and TCRγδ restricted. PB involvement by AITL appears to be more common and under-reported. Nevertheless, detection of these tumoral T lymphocytes needs to be assessed in large case studies for assessing the true incidence of PB involvement. FCM analysis is an effective and reliable approach in the identification of leukemic phase of AITL and can lead to timely and effective intervention. Competing Interests: None. (AJBR Copyright © 2020.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu